An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2013 Biomarkers information updated
- 03 Apr 2012 Actual patient number is 4 according to ClinicalTrials.gov.
- 03 Apr 2012 Actual end date changed from May 2010 to Jul 2009 as reported by ClinicalTrials.gov.